Requested symbol wasn't found

U.S. Markets closed

(RANBAXY.BO)


BSE - BSE Delayed Price. Currency in USD
Add to watchlist
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.00
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 years ago

    India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

    Sun Pharmaceutical Industries , India's largest drugmaker by revenue, on Thursday posted a 15 percent rise in quarterly net profit, roughly in line with expectations, helped by strong growth in sales in the domestic market. Sun Pharma's smaller rival Cipla, however, reported a 16 percent drop in its quarterly profit, hit by sluggish growth in income from exports, which accounts for more than half of its revenue.

  • Reuters3 years ago

    Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

    Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement. The companies will be allowed to set their own prices for the generic drug, and will pay a royalty on their earned sales to Gilead, it said.

  • We're sorry this is all we were able to find about this topic.